| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. | Cancer Discov | 2015 | 1.64 |
| 2 | Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. | Cancer Discov | 2015 | 1.30 |
| 3 | Dual Roles of RNF2 in Melanoma Progression. | Cancer Discov | 2015 | 0.86 |
| 4 | Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. | Cancer Res | 2015 | 0.86 |